SCHEMBL20695382

SCHEMBL20695382

Cc1cc(-c2ccccc2)sc1C(=O)N1CC2(CCC(=O)N2)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 1/20 0.38
▸ CD274 Q9NZQ7 2/20 0.38
▸ PDCD1LG2 Q9BQ51 1/20 0.38
▸ MGLL Q99685 3/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ PKM P14618 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ IKBKB O14920 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20695092 0.80 RAB9A (0.43) KDM4ERXFP1NPC1ALDH1A1RAB9A
SCHEMBL20695443 0.78 HTR3E (0.38) MGLLALDH1A1MEN1HPGDKMT2A
SCHEMBL20695396 0.78 PDCD1LG2 (0.37) HTR2CCD274PDCD1LG2MGLLMAPT
SCHEMBL20695299 0.78 GHSR (0.44) HTR2CCD274PDCD1LG2MGLLLMNA
SCHEMBL20695340 0.77 BRD4 (0.50) MGLLALDH1A1MEN1HPGDKMT2A
SCHEMBL20695312 0.77 MGLL (0.41) CD274PDCD1LG2MGLLALDH1A1PDCD1
SCHEMBL20695212 0.76 ALDH1A1 (0.41) CD274PDCD1LG2MGLLMAPTLMNA
SCHEMBL20695287 0.76 PRNP (0.41) MGLLMAPTLMNARXFP1ALDH1A1
SCHEMBL20695210 0.75 MAPK1 (0.50) LMNAALDH1A1MEN1HPGDKMT2A
SCHEMBL20695128 0.74 HDAC6 (0.41) MGLLALDH1A1MEN1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10610520-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-04-07 — — US disclosed
US-20190125728-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-02 — — US disclosed
US-20190125728-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-05-02 — — US disclosed
EP-3438109-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-02-06 — — EP disclosed
EP-3438109-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2019-02-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190125728-A1 HETEROCYCLIC COMPOUND MAG, HTT, ACHE HTR2C 572/4885CD274 403/4885PDCD1LG2 488/4885
US-10610520-B2 Heterocyclic compound MAG, HTT, ACHE HTR2C 572/4885CD274 403/4885PDCD1LG2 488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback